

Item 8.01 Other Events

Lexaria Bioscience Corp. (“Lexaria”) announced in its press releases of June 20 and July 19, 2023 the grants of its most recent US patents for the use of its proprietary DehydraTECH technology for the treatment of hypertension and for use with nicotine molecules in sublingual delivery formats. A summary of these most recently issued US patents is as follows:

US Patent #11,666,543 - *Pharmaceutical Compositions and Methods for Treating Hypertension*

US Patent #11,666,544 - *Compositions and Methods for Treating Hypertension*

These patents represent our first and second patents in our Patent Family #21 and the protection for both pharmaceutical compositions and non-pharmaceutical compositions, reinforce Lexaria’s commercial opportunities in the separate pharmaceutical and consumer markets. With our expected upcoming filing with the FDA of our Investigational New Drug application for the use of DehydraTECH-CBD for the treatment of hypertensive patients, the issuance of these patents comes at an opportune time for the Company.

US Patent #11,700,875 - *Compositions and Methods For Sublingual Delivery of Nicotine*

Lexaria’s mission is to provide healthier delivery methods of different drugs and other active ingredients through the use of its proprietary drug delivery technology DehydraTECH. Accordingly, the grant of this patent, which includes claims for many types of nicotine for use in sublingual delivery formats, is of particular importance in light of Lexaria’s current nicotine study, as detailed in our news release of May 8, 2023. Study NIC-H22-1 utilized a DehydraTECH enhanced nicotine oral pouch format which was compared against commercially available nicotine oral pouches, to validate our belief that DehydraTECH enhanced nicotine oral pouches will deliver nicotine to the user more effectively. Should our study results evidence this improved delivery, we believe that commercialized oral pouches with DehydraTECH enhanced nicotine could encourage current nicotine smokers and vapers to switch to this healthier format.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LEXARIA BIOSCIENCE CORP.

/s/ Chris Bunka

Chris Bunka
CEO, Principal Executive Officer

Date: July 20, 2023